anti icos mab  (Bio X Cell)

Journal: Journal of translational medicine

Article Title: Non-invasive imaging with ICOS-targeting monoclonal antibody for preclinical diagnosis of rheumatoid arthritis in a humanized mouse model.

doi: 10.1186/s12967-024-05899-w

Figure Lengend Snippet: Fig. 4 A Scheme of Cy7 NHS ester conjugation with anti-human ICOS monoclonal antibody (mAb). B The characterization of labeled antibody at differ ent concentrations. Relative fluorescence unit (RFU). C Cell uptake of Cy7-ICOS mAb in PMA/Iono activated, blocked, and resting T cells in huPBMCs at 1-hour incubation (n = 3). D MFI was measured to assess cellular uptake of the ICOS mAb labeled with Cy7 fluorophore at a concentration of 100nM. All values represent the mean ± SEM unless otherwise specified. One-way ANOVA and t test was conducted for statistical significance. ****, p < 0.0001; ***, p < 0.001; **, p < 0.01; *, p < 0.05; ns p > 0.05

Article Snippet: The supplier of the in vivo monoclonal antibody (BE0353, clone: C398.4 A) against human ICOS was BioXCell, located in West Lebanon, USA.

Techniques: Conjugation Assay, Labeling, Fluorescence, Incubation, Concentration Assay

Journal: Journal of translational medicine

Article Title: Non-invasive imaging with ICOS-targeting monoclonal antibody for preclinical diagnosis of rheumatoid arthritis in a humanized mouse model.

doi: 10.1186/s12967-024-05899-w

Figure Lengend Snippet: Fig. 5 A Reference of 4-view Regions of Interest (ROI) drawing was implemented, encompassing perspectives from the TOP, Bottom, Left, and Right orientations. B 4-view NIRF images at all time points (24 h, 48 h, 72 h, 96 h) between the huPBMC-AIA (n = 6) and control groups (n = 4). C X-ray and photographs images merge NIRF imaging following ICOS mAb-Cy7 injection at 6 h, 24 h, 48 h, 72 h and 96 h. D Fluorescence Intensity (FI) of four distinct views was systematically assessed at various time points. E ROI quantification of RP and the RP/LP ratio at all time points examined between huPBMC-AIA and control. F Correlation between paw thickness and RP/LP ratio in NIRF. Significant correlation was observed in both huPBMC-AIA and control group. All values represent the mean ± SEM unless otherwise specified. One-way ANOVA and t test was conducted for statistical significance. ****, p < 0.0001; ***, p < 0.001; **, p < 0.01; *, p < 0.05; ns p > 0.05

Article Snippet: The supplier of the in vivo monoclonal antibody (BE0353, clone: C398.4 A) against human ICOS was BioXCell, located in West Lebanon, USA.

Techniques: Control, Imaging, Injection, Fluorescence

Journal: Journal of translational medicine

Article Title: Non-invasive imaging with ICOS-targeting monoclonal antibody for preclinical diagnosis of rheumatoid arthritis in a humanized mouse model.

doi: 10.1186/s12967-024-05899-w

Figure Lengend Snippet: Fig. 6 A Ex vivo imaging in major organs (1 heart, 2 liver, 3 lung, 4 spleen, 5 kidney, 6 intestine, 7 right paw (RP), 8 left paw (LP), 9 bone, 10 muscle, 11 skin, and 12 blood) at day 7 right after the last in vivo NIRF scan (X-ray and photographs images). B Fluorescence intensity (FI) statistics were analyzed for both paw tissues and major organs following the intravenous administration of ICOS mAb labeled with Cy7 fluorophore at the 96 h time point. C Intra-group correlation analysis, the uptake and metabolism of the anti-human ICOS-Cy7 were evaluated. Row/column order determined by unsupervised hierarchi cal clustering. Side bars represent log10 (FI of organs) at 96 h. D Correlogram depicting r2 Pearson correlation between FI measured in the indicated ROI, compared with the log10 (fold-change RP/LP)at various time points. E Principal Component Analysis (PCA) involved the transformation of the data into principal components, enabling a comprehensive exploration of patterns and variations within the normalized ICOS NIRF signals. F ROC analysis showing sensitivity against 100%specificity for distinguishing the huPBMC-AIA from control group based on FI fold change imaged at 24 h and 96 h. All values represent the mean ± SEM unless otherwise specified. One-way ANOVA and t test was conducted for statistical significance. ****, p < 0.0001; ***, p < 0.001; **, p < 0.01; *, p < 0.05; ns p > 0.05

Article Snippet: The supplier of the in vivo monoclonal antibody (BE0353, clone: C398.4 A) against human ICOS was BioXCell, located in West Lebanon, USA.

Techniques: Ex Vivo, Imaging, In Vivo, Fluorescence, Labeling, Transformation Assay, Control

Journal: Cell Reports Medicine

Article Title: Spatially resolved transcriptomics reveal the determinants of primary resistance to immunotherapy in NSCLC with mature tertiary lymphoid structures

doi: 10.1016/j.xcrm.2025.101934

Figure Lengend Snippet:

Article Snippet: Anti-ICOS (D1K2T) Rabbit Monoclonal Primary Antibody , CST , 89601.

Techniques: Software, Clinical Proteomics, Imaging

Journal: iScience

Article Title: Lack of canonical thyroid hormone receptor α signaling changes regulatory T cell phenotype in female mice

doi: 10.1016/j.isci.2024.110547

Figure Lengend Snippet:

Article Snippet: Armenian hamster anti-ICOS monoclonal antibody; BB515 , BD Biosciences , Cat# 565881.

Techniques: Functional Assay, Recombinant, Cell Isolation, Staining, Luciferase, Plasmid Preparation, Software, Flow Cytometry, Electroporation

Journal: Frontiers in Immunology

Article Title: Manipulating regulatory T cells: is it the key to unlocking effective immunotherapy for pancreatic ductal adenocarcinoma?

doi: 10.3389/fimmu.2024.1406250

Figure Lengend Snippet: Phenotype of effector T reg cells in human PDAC. Effector T regs – characterised by the expression of FOXP3, CD25, TIGIT, CTLA-4, ICOS, CD39, and CCR8 – are activated by sustained TCR stimulation with abundant self- and quasi-self-antigens and stabilised by expression of the Helios transcription factor. These cells exhibit potent immunosuppressive capacity within the PDAC TME, where they exist in close proximity to CD8 + T lymphocytes. Specifically, they express co-inhibitory molecules (e.g., CTLA-4, TIGIT, ICOS); convert ATP to immunosuppressive adenosine via ectoenzymes that remain catalytically active after cell-death (CD39 and CD73); secrete immunosuppressive cytokines (e.g., IL-10, IL-35, TGF- β ) and granzymes that lyse CD8 + T eff cells; and sequester IL-2 that is required for T eff cell activation.

Article Snippet: Alomfilimab (KY1044) , Kymab/Sanofi , Agonistic ICOS monoclonal antibody , Phase I/II, +/- atezolizumab (anti-PD-L1), in patients with advanced solid tumours including PDAC , NCT03829501.

Techniques: Expressing, Activation Assay

Journal: Frontiers in Immunology

Article Title: Manipulating regulatory T cells: is it the key to unlocking effective immunotherapy for pancreatic ductal adenocarcinoma?

doi: 10.3389/fimmu.2024.1406250

Figure Lengend Snippet: T reg -targeted immunotherapies in current development (as of 01/05/2024).

Article Snippet: Alomfilimab (KY1044) , Kymab/Sanofi , Agonistic ICOS monoclonal antibody , Phase I/II, +/- atezolizumab (anti-PD-L1), in patients with advanced solid tumours including PDAC , NCT03829501.

Techniques: Recombinant